145 related articles for article (PubMed ID: 29274926)
21. Metastatic neuroblastoma in infants: are survival rates excellent only within the stringent framework of clinical trials?
Di Cataldo A; Agodi A; Balaguer J; Garaventa A; Barchitta M; Segura V; Bianchi M; Castel V; Castellano A; Cesaro S; Couselo JM; Cruz O; D'Angelo P; De Bernardi B; Donat J; de Andoin NG; Hernandez MI; La Spina M; Lillo M; Lopez-Almaraz R; Luksch R; Mastrangelo S; Mateos E; Molina J; Moscheo C; Mura R; Porta F; Russo G; Tondo A; Torrent M; Vetrella S; Villegas JA; Viscardi E; Zanazzo GA; Cañete A
Clin Transl Oncol; 2017 Jan; 19(1):76-83. PubMed ID: 27041689
[TBL] [Abstract][Full Text] [Related]
22. Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study.
Maris JM; Weiss MJ; Guo C; Gerbing RB; Stram DO; White PS; Hogarty MD; Sulman EP; Thompson PM; Lukens JN; Matthay KK; Seeger RC; Brodeur GM
J Clin Oncol; 2000 May; 18(9):1888-99. PubMed ID: 10784629
[TBL] [Abstract][Full Text] [Related]
23. Management and outcome of stage 3 neuroblastoma.
Modak S; Kushner BH; LaQuaglia MP; Kramer K; Cheung NK
Eur J Cancer; 2009 Jan; 45(1):90-8. PubMed ID: 18996003
[TBL] [Abstract][Full Text] [Related]
24. [Clinical characteristics and prognostic analysis of 458 children with high-risk neuroblastoma in a single center].
Su Y; Ma XL; Wang HM; Qin H; Qin MQ; Zhang FQ; Jin M; Zhang DW; Chen CH; Zeng Q; He LJ; Ni X
Zhonghua Er Ke Za Zhi; 2020 Oct; 58(10):796-801. PubMed ID: 32987457
[No Abstract] [Full Text] [Related]
25. Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers.
Oberthuer A; Juraeva D; Hero B; Volland R; Sterz C; Schmidt R; Faldum A; Kahlert Y; Engesser A; Asgharzadeh S; Seeger R; Ohira M; Nakagawara A; Scaruffi P; Tonini GP; Janoueix-Lerosey I; Delattre O; Schleiermacher G; Vandesompele J; Speleman F; Noguera R; Piqueras M; Bénard J; Valent A; Avigad S; Yaniv I; Grundy RG; Ortmann M; Shao C; Schwab M; Eils R; Simon T; Theissen J; Berthold F; Westermann F; Brors B; Fischer M
Clin Cancer Res; 2015 Apr; 21(8):1904-15. PubMed ID: 25231397
[TBL] [Abstract][Full Text] [Related]
26. Risk stratification of high-risk metastatic neuroblastoma: A report from the HR-NBL-1/SIOPEN study.
Morgenstern DA; Pötschger U; Moreno L; Papadakis V; Owens C; Ash S; Pasqualini C; Luksch R; Garaventa A; Canete A; Elliot M; Wieczorek A; Laureys G; Kogner P; Malis J; Ruud E; Beck-Popovic M; Schleiermacher G; Valteau-Couanet D; Ladenstein R
Pediatr Blood Cancer; 2018 Nov; 65(11):e27363. PubMed ID: 30015396
[TBL] [Abstract][Full Text] [Related]
27. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group.
London WB; Castleberry RP; Matthay KK; Look AT; Seeger RC; Shimada H; Thorner P; Brodeur G; Maris JM; Reynolds CP; Cohn SL
J Clin Oncol; 2005 Sep; 23(27):6459-65. PubMed ID: 16116153
[TBL] [Abstract][Full Text] [Related]
28. MYCN protein expression as a predictor of neuroblastoma prognosis.
Chan HS; Gallie BL; DeBoer G; Haddad G; Ikegaki N; Dimitroulakos J; Yeger H; Ling V
Clin Cancer Res; 1997 Oct; 3(10):1699-706. PubMed ID: 9815553
[TBL] [Abstract][Full Text] [Related]
29. HIF-1α up-regulation is associated with adverse clinicopathological and biological factors in neuroblastomas.
Dungwa JV; Hunt LP; Ramani P
Histopathology; 2012 Sep; 61(3):417-27. PubMed ID: 22571395
[TBL] [Abstract][Full Text] [Related]
30. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study.
Perez CA; Matthay KK; Atkinson JB; Seeger RC; Shimada H; Haase GM; Stram DO; Gerbing RB; Lukens JN
J Clin Oncol; 2000 Jan; 18(1):18-26. PubMed ID: 10623689
[TBL] [Abstract][Full Text] [Related]
31. Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification.
Krams M; Hero B; Berthold F; Parwaresch R; Harms D; Rudolph P
Cancer; 2002 Feb; 94(3):854-61. PubMed ID: 11857322
[TBL] [Abstract][Full Text] [Related]
32. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.
Schmidt ML; Lal A; Seeger RC; Maris JM; Shimada H; O'Leary M; Gerbing RB; Matthay KK
J Clin Oncol; 2005 Sep; 23(27):6474-80. PubMed ID: 16116154
[TBL] [Abstract][Full Text] [Related]
33. Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group project.
Mossé YP; Deyell RJ; Berthold F; Nagakawara A; Ambros PF; Monclair T; Cohn SL; Pearson AD; London WB; Matthay KK
Pediatr Blood Cancer; 2014 Apr; 61(4):627-35. PubMed ID: 24038992
[TBL] [Abstract][Full Text] [Related]
34. The prognostic significance of vanillylmandellic acid in neuroblastoma.
Aydin GB; Kutluk MT; Yalcin B; Varan A; Akyuz C; Buyukpamukcu M
Pediatr Hematol Oncol; 2010 Sep; 27(6):435-48. PubMed ID: 20578806
[TBL] [Abstract][Full Text] [Related]
35. Intensified external-beam radiation therapy improves the outcome of stage 4 neuroblastoma in children > 1 year with residual local disease.
Simon T; Hero B; Bongartz R; Schmidt M; Müller RP; Berthold F
Strahlenther Onkol; 2006 Jul; 182(7):389-94. PubMed ID: 16826357
[TBL] [Abstract][Full Text] [Related]
36. Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.
Kushner BH; Ostrovnaya I; Cheung IY; Kuk D; Modak S; Kramer K; Roberts SS; Basu EM; Yataghene K; Cheung NK
Oncotarget; 2016 Jan; 7(4):4155-66. PubMed ID: 26623730
[TBL] [Abstract][Full Text] [Related]
37. Prognostic impact of MYCN, DDX1, TrkA, and TrkC gene transcripts expression in neuroblastoma.
de Souza DR; Sanabani SS; de Souza AC; Filho Odone V; Epelman S; Bendit I
Pediatr Blood Cancer; 2011 May; 56(5):749-56. PubMed ID: 21154590
[TBL] [Abstract][Full Text] [Related]
38. Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma.
Haber M; Smith J; Bordow SB; Flemming C; Cohn SL; London WB; Marshall GM; Norris MD
J Clin Oncol; 2006 Apr; 24(10):1546-53. PubMed ID: 16575006
[TBL] [Abstract][Full Text] [Related]
39. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT
J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152
[TBL] [Abstract][Full Text] [Related]
40. High phosphohistone H3 expression correlates with adverse clinical, biological, and pathological factors in neuroblastomas.
Ramani P; Taylor S; Miller E; Sowa-Avugrah E; May MT
J Histochem Cytochem; 2015 Jun; 63(6):397-407. PubMed ID: 25711230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]